Navigation Links
EpiCept Reports Second Quarter 2013 Operating and Financial Results
Date:7/31/2013

t levels through the close of the merger with Immune.

Other Income (Expense)Other income (expense) in the second quarter of 2013 amounted to net expense of $0.2 million compared with net expense of $0.9 million in the second quarter of 2012.  Other income (expense) in the six months ended June 30, 2013 amounted to net expense of $0.4 million compared with net expense of $1.9 million in the six months ended June 30, 2012.  The primary component of other expense in 2013 was interest expense related primarily to the Company's senior secured term loan.  The primary components of other expense in 2012 were warrant amendment expense of $0.9 million, interest expense of $0.7 million related primarily to the Company's senior secured term loan and a foreign exchange loss of $0.3 million.

About EpiCept CorporationEpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of pain and cancer. The Company's pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.  The Company's product Ceplene®, when used concomitantly with low-dose IL-2, is intended as remission maintenance therapy in the treatment of AML for adult patients who are in their first complete remission.  The Company sold all of its rights to Ceplene® in Europe and certain Pacific Rim countries and a portion of its remaining Ceplene® inventory to Meda AB in June 2012.  Ceplene® is licensed to MegaPharm Ltd. to market and sell in Israel and EpiCept has retained its rights to Ceplene® in all other countries, including countries in North and South America.  The Company has other oncology drug candidates in clinical development that were discovered using in-house technology and have been show
'/>"/>

SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... Continuing Resolution Appropriations Act of 2015, which for the ... funding through the Congressionally Directed Medical Research Programs (CDMRP) ... Association (HA), working in conjunction with its allies on ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... for Reproductive Medicine (ASRM), a leading professional organization committed to ... new role as treasurer, Dr. Hill also fills a seat ... furthering the mission of ASRM. , Dr. Hill has ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... (Santa Barbara, Calif.) A team of physicists at UC ... many different colors. By aiming high- and low-frequency laser beams ... from their cores, accelerated, and then smashed back into the ... light simultaneously. Their findings appear in the current issue of ...
... 2012  Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology ... of patented technologies in the field of transplantation ... its subsidiary DiaKine Therapeutics Inc. received European patent ... be used to treat diabetes, atherosclerosis and other ...
... RIDGE, N.J., March 28, 2012  Regado Biosciences, Inc., a ... with active control agents, announced that David J. Mazzo, ... & Company,s 11th Annual Healthcare Conference at 10 a.m. ... Palace Hotel in New York City. The ...
Cached Biology Technology:UCSB Physicists mix 2 lasers to create light at many frequencies 2UCSB Physicists mix 2 lasers to create light at many frequencies 3Islet Sciences Announces DiaKine Therapeutics' Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection 2Islet Sciences Announces DiaKine Therapeutics' Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection 3Regado Biosciences, Inc. to Present at Needham & Company's 11th Annual Healthcare Conference in New York, NY 2Regado Biosciences, Inc. to Present at Needham & Company's 11th Annual Healthcare Conference in New York, NY 3
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... offering. One major trend emerging in ... Multimodal biometric systems utilize more than one characteristic of ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... process of aging disturbs a broad range of cellular mechanisms ... models using fuzzy logic might help to unravel these complexities ... to a study from Drexel University in Philadelphia and Children,s ... in aging is to develop integrated models of a unifying ...
... in newborn mice take around two weeks to become fully ... to understanding of the cold sensing protein TRPM8 (pronounced trip-em-ate), ... by David McKemy of the University of Southern California. ... cold sensing circuit starts to develop in utero but does ...
... shown fathers who are active in their children,s upbringing can ... being. Now, a new study by University of South ... is born may play an important role in preventing death ... infant is black. The USF team sought to ...
Cached Biology News:Fuzzy logic predicts cell aging 2When do newborns first feel cold? 2Father involvement in pregnancy could reduce infant mortality 2
From formula-fed bovine calves Sterile, Cell culture tested...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... may be carried out using this high ... System control and data processing is provided ... The elegant, powerful and very easy to use ... and 2000., The supplied automatic sample injector has ...
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
Biology Products: